Background: The design, optimization, and evaluation of a series of novel imidazopyridazine-based subtype-selective positive allosteric modulators (PAMs) for the GABAA ligand-gated ion channel are described.
Background: The design, optimization, and evaluation of a series of novel imidazopyridazine-based subtype-selective positive allosteric modulators (PAMs) for the GABAA ligand-gated ion channel are described.
You are now leaving cerevel.com, a website provided by Cerevel Therapeutics. The content displayed on external websites is not controlled by Cerevel, and Cerevel assumes no responsibility for the information or statements on external websites.